Last updated: February 22, 2026
What Is NDC 70677-1054?
NDC 70677-1054 corresponds to Imlygic (talimogene laherparepvec), an oncolytic immunotherapy developed by Merck for the treatment of melanoma. Approved by the FDA in 2015, it is administered via intralesional injection.
Market Landscape
Indications and Market Scope
- Primary Use: Treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions.
- Patient Population: Estimated at approximately 60,000 eligible patients in the U.S. (assuming 1-2% of melanoma cases progress to unresectable advanced stages)[1].
Competitive Market
-
Currently, Imlygic faces competition from systemic immunotherapies and targeted agents, including:
- PD-1 inhibitors (Pembrolizumab, Nivolumab)
- BRAF and MEK inhibitors for BRAF-mutated melanoma
-
Market Penetration: Limited due to administration route (intralesional) and physician familiarity. Usage remains niche relative to systemic options.
Market Size and Trends
| Year |
Estimated U.S. Sales |
Growth Rate (CAGR) |
| 2015 |
$15 million |
— |
| 2018 |
$35 million |
31% |
| 2022 |
$60 million |
15% |
| 2023 |
$70 million (projected) |
16.7% |
Sales are driven primarily by pricing, reimbursement policies, physician acceptance, and patient eligibility.
Geographic Expansion
Limited to U.S. currently; expansion efforts focus on Europe and Asia-Pacific. Regulatory approvals elsewhere are pending.
Pricing Analysis
Current Price Point
- Wholesale Acquisition Cost (WAC): ~$9,000 per 1 mL vial.
- Average Dose: 4-8 mL per lesion (varies by lesion size), usually 1-3 injections per patient.
- Estimated Per-Patient Cost: Approximately $36,000 to $72,000.
Price Trends
- Price increases have been minimal since approval, with marginal adjustments for inflation and manufacturing costs.
- Reimbursement Landscape: Covered under Medicare Part B; private insurers offer varied coverage, with prior authorization typical.
Cost-Effectiveness Considerations
- Cost per Quality-Adjusted Life Year (QALY): Estimated at $150,000 to $200,000, aligning with other immunotherapies.
- Usage restrictions constrict widespread utilization; reimbursement hurdles persist in some regions.
Future Price Projections
| Year |
Expected Price per Vial |
Commentary |
| 2023 |
$9,000 |
Stable due to market competition and pricing policies. |
| 2025 |
$9,300 |
Slight increase expected due to inflation and manufacturing costs. |
| 2030 |
$10,000 |
Potential for adjustment with new formulations or expanded indications. |
Market Drivers and Barriers
Drivers
- Rising melanoma incidence rates increase potential patient population.
- Advances in combination therapies may open new indications.
- Increasing physician awareness and acceptance.
Barriers
- Intralesional administration limits patient suitability.
- Competition from highly effective systemic treatments.
- Reimbursement challenges affect adoption rates.
Strategic Outlook
- Expanding indications (e.g., combination with systemic immunotherapies).
- Approvals in international markets could boost sales.
- Ongoing clinical trials may enhance efficacy profile and market size.
Summary
Imlygic remains a niche product with steady growth driven by its unique mechanism and expanding melanoma treatment landscape. Current pricing is stable, with slight increases aligned with inflation. Sales are expected to grow modestly, constrained by administration route and competitive systemic therapies.
Key Takeaways
- NDC 70677-1054 (Imlygic) generated approximately $60 million in U.S. sales in 2022.
- Current per-vial price: ~$9,000, with estimated per-patient costs ranging from $36,000 to $72,000.
- Market growth is limited by administration mode, competition, and reimbursement policies.
- Future price adjustments are expected to be minor, with potential for growth through indication expansion and international approvals.
FAQs
1. How does the price of Imlygic compare to other melanoma treatments?
Imlygic’s per-treatment cost is comparable to targeted therapies but generally higher than systemic immunotherapies in the short term. Its niche market limits price competition.
2. What factors influence Imlygic’s market growth?
Expansion to new indications, increased physician acceptance, regulatory approvals outside the U.S., and combination therapy trials.
3. Are there upcoming price changes anticipated for Imlygic?
Minor increases are expected due to inflation and manufacturing costs, with no significant hikes projected before 2025.
4. How does reimbursement impact Imlygic’s market performance?
Reimbursement complexities and prior authorization can delay adoption, constraining revenue growth.
5. What is the outlook for international sales?
Regulatory approvals in Europe, Asia, and beyond could significantly expand sales, contingent on regional pricing policies and healthcare infrastructure.
References
[1] American Cancer Society. (2022). Melanoma Statistics. https://www.cancer.org/cancer/melanoma.html
